Second generation drug‐eluting stents versus bare‐metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET‐PROVE I and II trials

To compare mid‐term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug‐eluting stent (DES) or bare‐metal stent (BMS).

[1]  N. Moat,et al.  Meta-Analysis of Percutaneous Coronary Intervention With Drug-Eluting Stent Versus Coronary Artery Bypass Grafting for Isolated Proximal Left Anterior Descending Coronary Disease. , 2016, The American journal of cardiology.

[2]  S. Bangalore.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease , 2016, The New England journal of medicine.

[3]  T. Akasaka,et al.  Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial , 2015, Circulation. Cardiovascular interventions.

[4]  F. Eberli,et al.  Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. , 2015, Circulation.

[5]  M. White,et al.  Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation , 2014, Cellular and Molecular Immunology.

[6]  Samin K. Sharma,et al.  Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. , 2014, Journal of the American College of Cardiology.

[7]  P. Serruys,et al.  Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial. , 2013, American heart journal.

[8]  Ajay K. Jain,et al.  Deployment of drug‐eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: A 5‐year observational cohort study , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  C. Terkelsen,et al.  Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.

[10]  G. Schuler,et al.  Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. , 2013, JACC. Cardiovascular interventions.

[11]  Deepak L. Bhatt,et al.  Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.

[12]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[13]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[14]  F. Eberli,et al.  Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.

[15]  C. Noel Bairey Merz,et al.  Women and ischemic heart disease: evolving knowledge. , 2009, Journal of the American College of Cardiology.

[16]  G. Schuler,et al.  Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. , 2009, Journal of the American College of Cardiology.

[17]  P. Serruys,et al.  Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. , 2008, American heart journal.

[18]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[19]  Ara Darzi,et al.  Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery , 2007, BMJ : British Medical Journal.

[20]  R. Mohr,et al.  Revascularization of left anterior descending artery with drug-eluting stents: comparison with minimally invasive direct coronary artery bypass surgery. , 2006, The Annals of thoracic surgery.

[21]  Carl J Pepine,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.

[22]  A. V. van Boven,et al.  Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  E. Varnauskas.  Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. , 1988, The New England journal of medicine.

[24]  L. Klein,et al.  Prognostic significance of severe narrowing of the proximal portion of the left anterior descending coronary artery. , 1986, The American journal of cardiology.